MarkFesenMDFACP

PubMed

• Albuterol-based premedication therapy for the prevention of cetuximab infusion-related reactions.
  Tra F, Fesen MR, Pianalto M, Nisly R> ;J. Clin. Oncol.. 2008-05-20
• 65 citations
  Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy
  Roger J. Waltzman, Christopher Croot, Glen R. Justice, Mark R. Fesen, Veena Charu, Denise Williams> ;The Oncologist. 2005 Sep 1
• Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: Preliminary results of a comparative trial.
  Waltzman RJ, Fesen M, Justice GR, Croot C, Williams D> ;J. Clin. Oncol.. 2004-07-15
• 21 citations
  Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors.
  John K. Buolamwini, Krishnamchari Raghavan, Mark R. Fesen, Yves Pommier, Kurt W. Kohn, John N. Weinstein> ;Pharmaceutical Research. 1996 Dec 1
• 112 citations
  (−)-Arctigenin as a Lead Structure for Inhibitors of Human Immunodeficiency Virus Type-1 Integrase
  Eckart Eich, Heinz H. Pertz, Macki Kaloga, Jutta Schulz, M. R. Fesen, A. Mazumder, Yves Pommier> ;Journal of Medicinal Chemistry. 1996 Jan 5
• 108 citations
  Hydroxylated aromatic inhibitors of HIV-1 integrase.
  Terrence R. Burke, Mark R. Fesen, Abhijit Mazumder, Jian Wang, A. M. Carothers, Dezider Grunberger, J. Driscoll, Kurt W. Kohn, Yves Pommier> ;Journal of Medicinal Chemistry. 1995 Oct 13
• 59 citations
  Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.
  K. Raghavan, John K. Buolamwini, Mark R. Fesen, Yves Pommier, Kurt W. Kohn, John N. Weinstein> ;Journal of Medicinal Chemistry. 1995 Mar 17
• 234 citations
  Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds
  Mark R. Fesen, Yves Pommier, François Leteurtre, Satoshi Hiroguchi, Jessie Yung, Kurt W. Kohn> ;Biochemical Pharmacology. 1994 Aug 3
• 38 citations
  Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase
  Abhijit Mazumder, Alan Engelman, Robert Craigie, Mark R. Fesen, Yves Pommier> ;Nucleic Acids Research. 1994 Mar 25
• 189 citations
  Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors
  Yves Pommier, D. Pharm, Mark R. Fesen, Akira Fujimori, Richard Bertrand, Eric Solary, Glenda Kohlhagen, Kurt W. Kohn> ;Cancer Investigation. 1994 Jan 1
• 1 citations
  The effects of cis-dichlorodiammine platinum on alkaline density gradient centrifugation of poly (dA) poly (dT)
  Mark R. Fesen, Harold C. Harder> ;Chemico-Biological Interactions. 1986 Jan 1
• Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA.
  Fesen, M., Pommier, Y.> ;J Biol Chem. 1989 Jul 5
• Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm.
  Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K. W., Pommier, Y.> ;Biochemistry. 1993 Aug 31
• Inhibitors of human immunodeficiency virus integrase.
  Fesen, M. R., Kohn, K. W., Leteurtre, F., Pommier, Y.> ;Proc Natl Acad Sci U S A. 1993 Mar 15
• Field-focusing hyperthermia and magnetic resonance imaging (MRI) with a grounded probe and a commercial MRI scanner.
  Yamanashi, W. S., Fesen, M. R., Anderson, D. W., SY, A. M., Lester, P. D.> ;Med Instrum. 1985 Sep 01
• Focused hyperthermia with a magnetic resonance imaging (MRI) unit and an interstitial grounded probe.
  Yamanashi, W. S., Fesen, M. R., Anderson, D. W., Valentine, J., Sy, A. M., Crandall, C., Lester, P. D.> ;Physiol Chem Phys Med NMR. 1984
• The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes.
  Rice, W. G., Schaeffer, C. A., Graham, L., Bu, M., McDougal, J. S., Orloff, S. L., Villinger, F., Young, M., Oroszlan, S., Fesen, M. R.> ;Proc Natl Acad Sci U S A. 1993 Oct 15
• Effects of DNA methylation on topoisomerase I and II cleavage activities.
  Leteurtre, F., Kohlhagen, G., Fesen, M. R., Tanizawa, A., Kohn, K. W., Pommier, Y.> ;J Biol Chem. 1994 Mar 18
• Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
  Deitcher, S. R., Fesen, M. R., Kiproff, P. M., Hill, P. A., Li, X., McCluskey, E. R., Semba, C. P.> ;J Clin Oncol. 2002 Jan 1
• Join now to see all

Journal Articles

• Waltzman, R., Croot, C., Justice, GR., Fesen, MR., Charu, V., Williams, D., Oncologist, 1/1/2005
• Deitcher, SR., Fesen, MR., Kiproff, PM., Hill, PA., Li, X., Semba, CP., Journal of Clinical Oncology, 1/1/2002
• Eich, E., Pertz, H., Kaloga, M., Schulz, J., Fesen, M., Mazumder, A., and Pommier, Y., Journal of Medicinal Chemistry, 1/1/1996
• Buolamwini, JK., Raghavan, K., Fesen, MR., Pommier, Y., Kohn, KW., Weinstein, JN., Pharmeceutical Research, 1/1/1996
• Fesen MR, Oncology, 1/1/1995
• Burke, TR Jr., Fesen, M., Mazumder, A., Wang, J., Carothers, A., Grunberger, D., Driscoll, J., Kohn, K., Pommier, Y, Journal of Medicinal Chemistry, 1/1/1995
• Raghavan, K., Buolamwini, J., Fesen, M., Pommier, Y., Kohn, K., Weinstein, J., Journal of Medicinal Chemistry, 1/1/1995
• Fesen, M., Pommier, Y., Leteurtre, F., Hiroguchi, S., Yung, J., and Pommier, Y., Biochemical Pharmacology, 1/3/1994
• Eich, E., Pertz, M., Kaloga, M., Schulz, J., Fesen, MR., Mazumder, A., Pommier, Y., European Journal of Pharmaceutical Sciences, 1/1/1994
• Leteurtre, F., Kohlhagen, G., Fesen, M., Tanizawa, A., Kohn, K., and Pommier, Y., Journal of Biological Chemistry, 1/1/1994
• Mazumber, R., Engleman, A., Craigie, R., Fesen, M., Pommier, Y., Nucleic Acids Research, 1/1/1994
• Letuertre, F., Fesen, M., Kohlhagen, G., Kohn, K., and Pommier, Y, Biochemistry, 1/31/1993
• Pommier, Y., Leteurtre, F., Fesen, M., Fujimori, A., Bertrand, R., Solary, E., and Kohn, K., Cancer Investigations, 1/9/1993
• Fesen, M., Kurt Kohn, Francois Leteurtre, and Yves Pommier, Proceedings of the National Academy of Science (USA), 1/1/1993
• Rice, W., Schaeffer, C., Graham, L., Bu, M., McDougal, S., Orloff, S., Villinger, F., Young, M., Oroszlan, S., Fesen, M., Pommier, Y., Mendeleyev, J., Kun, E., Proceedings of the National Academy of Science (USA), 1/1/1993
• Fesen, M., and Harder, H., Chemicobiological Interactions, 1/1/1989
• Fesen, M., and Pommier, Y., Journal of Biological Chemistry, 1/1/1989
• Yamanshi, W., Fesen, M., Anderson, D., Valentine, J., Sy, A., Crandell, C., and Lester, P., Physiological Chemistry and Physics and Medical NMR, 1/1/1984
• Join now to see all

Books/Book Chapters

•  
  Fesen MRAMACOM American Management Association, New York, NY2009
•  
  Chapter: Topoisomerase II inhibitors 
  Pommier, Y., Fesen, M., and Goldwasser, F.Editors: Chabner, B. and Long, D..Lippincott-Raven Publishers1996

Abstracts/Posters

• Tra, F., Fesen, MR., Pianalto, M., Nisly., R., Journal of Clinical Oncology; ASCO Annual Meeting Proceedings, 1/1/2008
• Waltzman, RJ., Fesen, MR., Justice, GR., Croot, C., Williams, D., Journal of Clinical Oncology; ASCO Annual Meeting Proceedings, 1/1/2004
• Blayney, DW., Spiridonidis, H., Fesen, MR., McGuire, WP., Bhatia, AW., Hellman, RM., Terry, D., Tomita, D., American Society of Clinical Oncology, 1/1/2003

Lectures

•  
  New York University, New York, NY - 1/1/1994
•  
  Orlando, FL - 1/1/1993
•  
  New Orleans, LA - 1/1/1988